Merck & Company Inc (MRK)vsRigel Pharmaceuticals Inc (RIGL)
MRK
Merck & Company Inc
$143.93
-0.54%
HEALTHCARE · Cap: $355.10B
RIGL
Rigel Pharmaceuticals Inc
$47.24
-0.08%
HEALTHCARE · Cap: $909.15M
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 23951% more annual revenue ($66.57B vs $276.79M). RIGL leads profitability with a 116.3% profit margin vs 4.8%. RIGL trades at a lower P/E of 2.9x. RIGL earns a higher WallStSmart Score of 54/100 (C-).
MRK
Hold36
out of 100
Grade: F
RIGL
Buy54
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-73.7%
Fair Value
$82.84
Current Price
$143.93
$61.09 premium
Margin of Safety
+86.1%
Fair Value
$251.76
Current Price
$47.24
$204.52 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Generating 4.5B in free cash flow
Attractively priced relative to earnings
Every $100 of equity generates 76 in profit
Keeps 116 of every $100 in revenue as profit
Conservative balance sheet, low leverage
Reasonable price relative to book value
Strong operational efficiency at 29.9%
Areas to Watch
Trading at 8.5x book value
ROE of 7.6% — below average capital efficiency
4.8% margin — thin
Elevated debt levels
Smaller company, higher risk/reward
Revenue declined 22.6%
Earnings declined 73.2%
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Free Cash Flow.
Bull Case : RIGL
The strongest argument for RIGL centers on P/E Ratio, Return on Equity, Profit Margin. Profitability is solid with margins at 116.3% and operating margin at 29.9%.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 116.1x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.
Bear Case : RIGL
The primary concerns for RIGL are Market Cap, Revenue Growth, EPS Growth.
Key Dynamics to Monitor
MRK profiles as a value stock while RIGL is a declining play — different risk/reward profiles.
RIGL carries more volatility with a beta of 1.20 — expect wider price swings.
MRK is growing revenue faster at 5.1% — sustainability is the question.
MRK generates stronger free cash flow (4.5B), providing more financial flexibility.
Bottom Line
RIGL scores higher overall (54/100 vs 36/100), backed by strong 116.3% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Rigel Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat blood disorders, cancer, and rare immune diseases. The company is headquartered in South San Francisco, California.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?